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Objectives: Lung-transplantation is since 1990 a treatment option for end-stage lung
disease in Sweden and at two transplant centres (Lund and Gothenburg). During the
last years extra corporeal membrane oxygenation (ECMO) has enabled survival in
otherwise dying patients and methods for re-conditioning have increased the donor
pool. Our aim was to assess the outcome of lung transplantation for CF with focus
on early complications.
Methods: Review of databases and patient charts.
Results: From 1990 to 2013 there were 105 transplantations performed in 96
patients with CF (9 re-transplantations); 2 heart-lung, 92 double-lung (1/92 lobar)
and 11 single lung. This constituted 13% (105/847) of the procedures performed at
the centres with a higher proportion CF for Lund (58/284) compared to Gothenburg
(47/561). The mean age at surgery was 31.4±10 (range 10−61) years and there
were 46% females. The mean patient survival after transplantation was 12.4 years
(95%CI 10.3–14.6), median 14.6 years (95%CI 9.8–19.4), and there was no
signiﬁcant difference for gender or transplant centre (Kaplan Meyer and Log rank
test). Conditional on survival to one month the mean survival was 13.1 (95%CI
11–15.3) and median 14.6 (95%CI 9.8–19.4) years. ECMO was used as a bridge to
transplantation in 8 cases and 6 patients received reconditioned lungs. Vascular and
infectious complications contributed to ﬁve deaths within the ﬁrst post-operative
month. The median waiting time was 136 (1–1865) days. There were 19 deaths on
the waiting list at median 94 (4–1005) days after listing.
Conclusion: Survival after lung transplantation is acceptable and comparable to
international data.
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Objectives: To assess the bacterial ﬂora in the airways before and after lung
transplantation (LTx).
Methods: Fifty-eight LTx in 52 patients with CF were performed 1992–2013
(48% female, 6 retransplantations, mean age 32). Cultures, performed before and
after LTx were examined for bacteria, fungi and mycobacteria. Cultures were
performed in all patients from NPH, sputum, sinus (if surgery before Ltx) and
BAL (if broncoscopy was performed before Ltx). After LTx, cultures from BAL
were performed in all patients at 3 and 6 months and when rejection or major
infection was suspected or from sputum.
Results: Prior to LTx all but one patient had positive cultures of Pseudomonas
aeruginosa (PsA) in upper and/or lower airways. Four patients had Burkholderia
cepacia or cenocepacia, ﬁfteen had Staphyloccous aureus (SA) and one patient had
NTM (none with M. abscessus). After LTx, 50 patients had recurrence of PsA or
Burkholderia. Only two patients had recurrence of SA, although six naı¨ve patients
acquired SA. Thirty-four of 52 patients were still alive (mean survival 13.7 years,
median survival 16.2 years). Most patients had positive cultures immediately
postoperative which then gradually disappeared and were only found intermittently
in sputum or BAL during follow up. There was no correlation between colonization
and outcome. Most patients recolonized with bacteria did not have any symptoms
of clinical infection.
Conclusion: Almost all patients with LTx due to cystic ﬁbrosis are recolonized
with PsA in the lower airways. We believe the sinus and upper airways are the
source, which then contaminates the lower airways without clinical symptoms of
infection.
